Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTScVZ5UUN3ME21Mlg3PjZizszN MXfTRW5ITVJ?
DOHH-2 NHnKXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTlwM{W2PFkh|ryP NXzLbolsW0GQR1XS
no-10 NVvDWFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m2VGlEPTB;OT65NFM6KM7:TR?= M1vWPXNCVkeHUh?=
LS-513 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3DPIFKSzVyPUGxMlM2PDdizszN M1nHT3NCVkeHUh?=
ALL-PO M2fB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPVTWM2OD1zMT63O|M1KM7:TR?= M1TUXXNCVkeHUh?=
8-MG-BA MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne2TWM2OD1zMz6xNVI{KM7:TR?= MoXtV2FPT0WU
RPMI-8402 NUnWRYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XVV2lEPTB;MUWuPFU{PyEQvF2= NFe4W2JUSU6JRWK=
EoL-1-cell M3\MRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF6LkW5OFgh|ryP M1jJRXNCVkeHUh?=
NALM-6 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XTfGlEPTB;MUmuNFE3PyEQvF2= M4XSTXNCVkeHUh?=
DEL M3fERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnMcWV[UUN3ME2yNE4yPDdzIN88US=> MmrUV2FPT0WU
SR M1;QO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ|Lk[3NVUh|ryP NWH5c|ZuW0GQR1XS
697 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ4Lk[xOVUh|ryP MYnTRW5ITVJ?
COLO-829 NYXEWmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HiTmlEPTB;Mk[uPFQ5OyEQvF2= MlrDV2FPT0WU
EVSA-T M2HXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvPTWM2OD1{Nz61OVYyKM7:TR?= MnvmV2FPT0WU
ATN-1 NGPyNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi4R2tKSzVyPUOxMlI{OjlizszN M1\qe3NCVkeHUh?=
L-363 NWG1d2t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjNVplyUUN3ME2zNU44PDZzIN88US=> NIi0S|dUSU6JRWK=
LAMA-84 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr3TWM2OD1|Mj61NlEyKM7:TR?= NIP0fnBUSU6JRWK=
NOS-1 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDydplJUUN3ME2zOE4zQTV4IN88US=> NHHEelJUSU6JRWK=
BB30-HNC M4H6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnQfXpxUUN3ME2zOE4{OzB4IN88US=> Mmr1V2FPT0WU
BC-1 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN5Lkm3OFYh|ryP NH3OcGxUSU6JRWK=
IST-SL2 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN6LkKyOEDPxE1? Mon0V2FPT0WU
D-392MG NY\4ZphPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXRdpRKSzVyPUSwMlIzOTVizszN MluyV2FPT0WU
no-11 NUPpSXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD12MD61OVIyKM7:TR?= M3;MPHNCVkeHUh?=
LC4-1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpfGlEPTB;NECuPFcyPiEQvF2= NVvQSWxxW0GQR1XS
A388 M2jqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD12Mj61PFQ5KM7:TR?= NYfie5Y3W0GQR1XS
NTERA-S-cl-D1 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfxb5lKSzVyPUSyMlcxPzRizszN NEDs[YRUSU6JRWK=
CESS MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7qXodKSzVyPUS0MlIzOzJizszN Mlr2V2FPT0WU
RS4-11 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjOd4xKSzVyPUS5MlA6OzhizszN NI\l[XVUSU6JRWK=
MS-1 NH75OWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPUTXVKSzVyPUWwMlk{PTFizszN NX;LO2Q3W0GQR1XS
CTV-1 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVzLkC3OEDPxE1? NGjWbW1USU6JRWK=
D-502MG NYjIS2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jib2lEPTB;NUGuOlI4OSEQvF2= NXz1[W5bW0GQR1XS
ML-2 NH;5VmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33OXGlEPTB;NUKuPVE6PSEQvF2= NE[0elZUSU6JRWK=
SK-NEP-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPBR2dNUUN3ME21N{4{QTJ|IN88US=> Mo\lV2FPT0WU
LOXIMVI NEG3PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfHb|lKSzVyPUWzMlU5QDRizszN MVLTRW5ITVJ?
DJM-1 NVHSdFBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KwPGlEPTB;NU[uN|M6OSEQvF2= MYTTRW5ITVJ?
GI-1 M4DCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1znT2lEPTB;NU[uOlE1QSEQvF2= NW\CeHpnW0GQR1XS
IST-MES1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jlc2lEPTB;NkCuOVQ6OyEQvF2= MknnV2FPT0WU
MV-4-11 M3zHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjQbWZKSzVyPU[wMlY2OzhizszN M{TpW3NCVkeHUh?=
OVCAR-4 M4\E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZ|LkW2OVch|ryP NYLSd29CW0GQR1XS
KE-37 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7ld4VMUUN3ME22Ok4zPjZ6IN88US=> NWPsVXNCW0GQR1XS
D-542MG NILxNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;RfolnUUN3ME22PE41OTN3IN88US=> M1flTXNCVkeHUh?=
MHH-PREB-1 M3HRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHOTWM2OD15Mj64OFQyKM7:TR?= NHzaUIpUSU6JRWK=
MRK-nu-1 NHjKV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLwTWM2OD15Mz60O|A2KM7:TR?= M1zwS3NCVkeHUh?=
D-247MG M2DqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;aOWlEPTB;N{OuOVQ1OiEQvF2= NUHYNnp2W0GQR1XS
OCI-AML2 NEPU[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTd4LkmzOlkh|ryP M3KyR3NCVkeHUh?=
LP-1 NFjZXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KwR2lEPTB;OEKuPFc{OSEQvF2= MWPTRW5ITVJ?
HCC1599 NIDZPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\BcWlEPTB;OESuNlg{PyEQvF2= M3:5VXNCVkeHUh?=
KARPAS-45 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjsUVBKSzVyPUi0MlY6QTJizszN M{P3W3NCVkeHUh?=
BE-13 M{jFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;lTWM2OD17OT6wOFc4KM7:TR?= NYHFSZBbW0GQR1XS
GCIY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS1TWM2OD17OT6wPVU1KM7:TR?= Mk[0V2FPT0WU
BV-173 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\TTWM2OD1zMECuN|I2KM7:TR?= M3XrPHNCVkeHUh?=
LB2518-MEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqybGxKSzVyPUGwNE44QDlizszN M1LGXXNCVkeHUh?=
KS-1 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XMWGlEPTB;MUCxMlY{QSEQvF2= NXS4dFFsW0GQR1XS
MOLT-16 NWfnUmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq2TWM2OD1zMESuPVg3KM7:TR?= NFvjRXhUSU6JRWK=
NCI-H1770 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO1[5hKSzVyPUGwPE44QDRizszN Mo\hV2FPT0WU
NCI-H82 NHjuZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFzMD65O|Yh|ryP NUP6WWVTW0GQR1XS
NCCIT MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjFNm5lUUN3ME2xNVIvPTJ7IN88US=> NEPMd3JUSU6JRWK=
KALS-1 M4XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFzNT65OFEh|ryP M1fOXnNCVkeHUh?=
LB2241-RCC M3PtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\JTWM2OD1zMU[uOlc6KM7:TR?= M1PQS3NCVkeHUh?=
HH M3PZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDoSmRFUUN3ME2xNVcvOzl3IN88US=> M37KNXNCVkeHUh?=
HD-MY-Z M{jaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrITWM2OD1zMUiuOFg5KM7:TR?= MnvWV2FPT0WU
EB-3 M3LOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe3Om9KSzVyPUGyN{4xQTRizszN MWnTRW5ITVJ?
BL-70 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxe4FKSzVyPUGyN{4yOjdizszN MlfzV2FPT0WU
K-562 NUHKeVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;DU29oUUN3ME2xNlYvOjR3IN88US=> NVH4dYFVW0GQR1XS
HT-144 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PrdWlEPTB;MUOzMlE3PCEQvF2= NEHlZ|lUSU6JRWK=
PF-382 NYfWfoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHtW|lKSzVyPUGzOE4{PjFizszN MUnTRW5ITVJ?
RPMI-8226 NGfRTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTKXo5KSzVyPUGzOU4xPDVizszN MmX5V2FPT0WU
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4fJFNUUN3ME2xN|UvPTh5IN88US=> M4TCU3NCVkeHUh?=
LXF-289 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PuZ2lEPTB;MUO5Mlc5OSEQvF2= MmnZV2FPT0WU
NCI-H69 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF2Mj65N|Ih|ryP NFnS[3VUSU6JRWK=
SK-MEL-1 M2LO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHGT5NFUUN3ME2xOFcvOTNizszN MmnyV2FPT0WU
KARPAS-299 NEPMOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXWemF5UUN3ME2xOFkvOTJizszN NXvOOIFJW0GQR1XS
GB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHrepl2UUN3ME2xOFkvOzJ{IN88US=> NF3pSY9USU6JRWK=
CMK M2P3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHrbWxKSzVyPUG0PU42OTVizszN MlH0V2FPT0WU
MPP-89 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DkNGlEPTB;MUW2MlA{PSEQvF2= M3jqcXNCVkeHUh?=
KU812 NF71R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF4MT65NFIh|ryP MnK0V2FPT0WU
REH MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLYTWM2OD1zNkKuNVI2KM7:TR?= MnG0V2FPT0WU
NEC8 M3PaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW2XppKSzVyPUG2OU4xOjZizszN M4\1PHNCVkeHUh?=
KP-N-YS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF4OD6zPVUh|ryP NYHxSYRIW0GQR1XS
Ramos-2G6-4C10 NWnkPGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonrTWM2OD1zNkmuPVE2KM7:TR?= MVjTRW5ITVJ?
Becker NUPpc|FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dw[mlEPTB;MUe0MlE5KM7:TR?= NEXOVXhUSU6JRWK=
LB647-SCLC NEnxPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEPGlEPTB;MUe1Mlg1PSEQvF2= MVXTRW5ITVJ?
LU-139 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvKOZVKSzVyPUG3PE4xOTlizszN NH\rTGpUSU6JRWK=
QIMR-WIL M4K1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF5OT62OFYh|ryP NGrMdmpUSU6JRWK=
NCI-H1395 M2PEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF5OT65PVYh|ryP Mk\VV2FPT0WU
NOMO-1 NXywe3dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjNTWM2OD1zOEKuPFUh|ryP MmDHV2FPT0WU
GI-ME-N NXPBPVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF6Nz65Olkh|ryP NHrUcm1USU6JRWK=
KMS-12-PE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWyXmdjUUN3ME2xPFkvOjd|IN88US=> M3LES3NCVkeHUh?=
Daudi Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\lPVZTUUN3ME2xPVEvOTJ6IN88US=> M1;1WnNCVkeHUh?=
LB996-RCC NX71O2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPiTWM2OD1zOUGuOlk6KM7:TR?= M2PQfHNCVkeHUh?=
NCI-H2107 NHf5UlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF7Mz63N|kh|ryP NHewUHNUSU6JRWK=
SK-PN-DW M2nPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHwb4x4UUN3ME2xPVQvPzF7IN88US=> NFr0NFhUSU6JRWK=
MC-CAR M{C0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJyMj6yOVMh|ryP NXTtbXJDW0GQR1XS
SNB75 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG3TWM2OD1{MkGuPVQh|ryP NUfzPWdxW0GQR1XS
ES4 NEn0SppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\OUW9VUUN3ME2yNlMvPzh|IN88US=> NI\iZYtUSU6JRWK=
KARPAS-422 NWnrV2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ{OD6zOVIh|ryP NEm2RXhUSU6JRWK=
NCI-H1648 NF2zOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ITWM2OD1{MkmuOFg6KM7:TR?= MYjTRW5ITVJ?
ES6 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\JXmtKSzVyPUKzPU41OyEQvF2= MnfEV2FPT0WU
KNS-81-FD M2XHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXrfHlKSzVyPUK0NU4yQTdizszN M2nOU3NCVkeHUh?=
JAR NGntXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LPWWlEPTB;MkW2MlIzPSEQvF2= M33IcXNCVkeHUh?=
NB1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\FTWM2OD1{NkCuOVE3KM7:TR?= M4XQc3NCVkeHUh?=
D-336MG MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF36Uo5KSzVyPUK2NE43QThizszN M{m3V3NCVkeHUh?=
BC-3 M1zVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ4NT6xO|gh|ryP MXrTRW5ITVJ?
HCC2218 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1TWM2OD1{Nk[uOFE2KM7:TR?= NHHkRVBUSU6JRWK=
TE-9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M363PWlEPTB;Mk[2MlYzPyEQvF2= M3XOPHNCVkeHUh?=
LB1047-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD4TWM2OD1{Nk[uO|U{KM7:TR?= M3vudXNCVkeHUh?=
CTB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ4OT65O|Mh|ryP NYTWc21JW0GQR1XS
NB7 M1LW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\QbWlEPTB;MkexJO69VQ>? NGi4R3VUSU6JRWK=
ST486 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPtS2dSUUN3ME2yO|cvPDF{IN88US=> NXLUNIJ2W0GQR1XS
HCC1187 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvrTWM2OD1{OEKuPFEyKM7:TR?= NGLNdlZUSU6JRWK=
NCI-SNU-16 M3HZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsb2pJUUN3ME2yPFQvOjR6IN88US=> NFXTbFdUSU6JRWK=
COR-L279 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTjTFU5UUN3ME2yPVEvPTh2IN88US=> Mn23V2FPT0WU
ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ocoZKSzVyPUK5OE4yQDJizszN MVnTRW5ITVJ?
U-698-M M2m0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3O3JUUUN3ME2yPVgvOjR|IN88US=> NUPYSnpiW0GQR1XS
HEL NFLnPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvSd4dqUUN3ME2zNFkvOTR7IN88US=> NYrpcnBDW0GQR1XS
KINGS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNzMD62O|Qh|ryP MWPTRW5ITVJ?
KY821 NXH1WVlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[yTWM2OD1|M{[uOVk2KM7:TR?= NGjS[olUSU6JRWK=
MZ1-PC NUflfYxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrEOo5bUUN3ME2zOFUvPjF6IN88US=> Mlf4V2FPT0WU
LS-411N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO4[FZzUUN3ME2zOVQvPjZizszN M1TVVXNCVkeHUh?=
SIG-M5 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLwU3FKSzVyPUO1PU44QDJizszN M1fObnNCVkeHUh?=
HT NFrSbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:1SWlEPTB;M{[3MlcyOSEQvF2= MXXTRW5ITVJ?
HC-1 M2jkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjC[IlKSzVyPUO2O{44QDdizszN NYW3N4o4W0GQR1XS
NCI-H1694 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi5OmVKSzVyPUO3Nk46OzRizszN NFvvZldUSU6JRWK=
BB65-RCC MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN5Nj6yOFUh|ryP MYPTRW5ITVJ?
HAL-01 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPEVZBKSzVyPUO3PU45OzhizszN MXfTRW5ITVJ?
ARH-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1|OUSuNFA5KM7:TR?= MUfTRW5ITVJ?
MZ7-mel MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN7Nz6yN|Mh|ryP MmXHV2FPT0WU
SIMA NWPPcXZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf5VXJKSzVyPUSwN{46OzNizszN NW[3Tox6W0GQR1XS
DG-75 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r5SWlEPTB;NEG1MlY6QCEQvF2= MVnTRW5ITVJ?
HUTU-80 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PubWlEPTB;NEG5MlE5PSEQvF2= NIPlWXZUSU6JRWK=
KNS-42 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX2c5pUUUN3ME20NlUvQDF3IN88US=> NHiwSJFUSU6JRWK=
SH-4 NHXWRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPwVpRKSzVyPUSyO{42PjVizszN NEjXZ5JUSU6JRWK=
L-540 NVe3b2szT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljiTWM2OD12M{GuNFMyKM7:TR?= MXzTRW5ITVJ?
NB10 NEDZbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR2MT6yN|Qh|ryP MUHTRW5ITVJ?
ES1 M4Tid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDjXoVQUUN3ME20OVIvPzV|IN88US=> MnHTV2FPT0WU
KMOE-2 NHSyRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR3Nj63NVEh|ryP M1[ybnNCVkeHUh?=
MC116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\xeHpzUUN3ME20OVgvOTF4IN88US=> NIfqfYtUSU6JRWK=
RCC10RGB M3W1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITyZZlKSzVyPUS2NE4xODVizszN M1n5OnNCVkeHUh?=
RL95-2 NVPSPIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHXTWM2OD12NkCuNlM4KM7:TR?= NGj6PHhUSU6JRWK=
Raji MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXyR3lKSzVyPUS2PE4yPDNizszN M13P[nNCVkeHUh?=
CAS-1 NYPqc4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjKTWM2OD12N{KuNFc{KM7:TR?= MW\TRW5ITVJ?
Calu-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6S4ZKSzVyPUS3OU4zPjVizszN NYrobml1W0GQR1XS
KG-1 NHLjUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnMcY9IUUN3ME20O|gvPDRizszN M2jvbXNCVkeHUh?=
LB771-HNC MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonmTWM2OD12OEKuNlMzKM7:TR?= NHTvVZpUSU6JRWK=
ACN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3THeWlEPTB;NEmzMlU6QSEQvF2= Mln6V2FPT0WU
KM12 NIe4VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\HNpBKSzVyPUS5Ok42QDlizszN M4C1T3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID